
==== Front
Intern Emerg Med
Intern Emerg Med
Internal and Emergency Medicine
1828-0447
1970-9366
Springer International Publishing Cham

38992323
3705
10.1007/s11739-024-03705-5
CE-Systematic reviews and meta-analysis
Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis
Mantovani Alessandro 1
Morandin Riccardo 1
Fiorio Veronica 1
Lando Maria Giovanna 1
Petta Salvatore 2
Ferraro Pietro Manuel 3
http://orcid.org/0000-0002-4325-3900
Targher Giovanni giovanni.targher@univr.it

45
1 https://ror.org/039bp8j42 grid.5611.3 0000 0004 1763 1124 Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy
2 https://ror.org/044k9ta02 grid.10776.37 0000 0004 1762 5517 Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy
3 https://ror.org/039bp8j42 grid.5611.3 0000 0004 1763 1124 Section of Nephrology, Department of Medicine, University of Verona, Verona, Italy
4 https://ror.org/039bp8j42 grid.5611.3 0000 0004 1763 1124 Department of Medicine, University of Verona, Verona, Italy
5 grid.416422.7 0000 0004 1760 2489 Metabolic Diseases Research Unit, IRCCS Sacro Cuore, Don Calabria Hospital, Viale Luigi Rizzardi, 4, 37024 Negrar di Valpolicella (VR), Italy
11 7 2024
11 7 2024
2024
19 6 17451755
21 5 2024
3 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Epidemiological studies have reported an association between metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of urolithiasis. However, the magnitude of the risk and whether this risk varies with the severity of MASLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between MASLD and urolithiasis. We systematically searched PubMed, Scopus, and Web of Science from database inception to March 31, 2024, using predefined keywords to identify relevant observational studies in which imaging methods or survey questionnaires diagnosed MASLD and urolithiasis. Meta-analysis was performed using random-effects modelling. We identified seven cross-sectional studies and one prospective cohort study with aggregate data on 248,936 adults from different countries. MASLD was significantly associated with an increased risk of prevalent urolithiasis (pooled random-effects odds ratio 1.87, 95% CI 1.34–2.60; I2 = 91%). This association remained significant in those studies whose results were adjusted for age, sex, ethnicity, obesity, diabetes, and other potential confounders. There was a positive graded association between the ultrasonographic severity of MASLD and urolithiasis. Meta-analysis of the single prospective cohort study showed that MAFLD was not associated with risk of developing incident urolithiasis (pooled random-effects hazard ratio 1.08, 95% CI 0.90–1.30), although a significant association was reported in men. Sensitivity analyses did not modify these findings. The funnel plot did not reveal any significant publication bias. This updated meta-analysis provides evidence for a significant association between MASLD and the presence of urolithiasis. Whether MASLD is associated with a higher risk of developing incident urolithiasis remains to be established.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11739-024-03705-5.

Keywords

Nonalcoholic fatty liver disease
NAFLD
Metabolic dysfunction-associated steatotic liver disease
MASLD
Urolithiasis
Renal stones
Meta-analysis
Università degli Studi di VeronaOpen access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.

issue-copyright-statement© Società Italiana di Medicina Interna (SIMI) 2024
==== Body
pmcIntroduction

Non-alcoholic fatty liver disease (NAFLD), recently renamed as metabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as a public health threat as it affects up to ~ 38% of the adult population worldwide [1–3], with its global prevalence rising in parallel with that of obesity and metabolic syndrome. An estimated ~ 50% of the worldwide adult population is forecasted to have MASLD by 2040 [2]. In 2023, using a multi-society Delphi process that involved 236 panelists from 56 countries, three large pan-national liver associations (i.e., the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Latin American Association for the Study of the Liver) have endorsed the newly proposed change in nomenclature from NAFLD to MASLD [1]. Therefore, for sake of clarity, we have opted to use the term MASLD throughout the manuscript.

Beyond its liver health implications, a rapidly expanding body of evidence indicates that MASLD is a multisystem disease extending its adverse effects beyond the liver [4, 5], and has been associated with an increased risk of developing extrahepatic cancers (mainly gastrointestinal and gynecological cancers) [6] and cardiometabolic comorbidities, such as type 2 diabetes [7], adverse cardiovascular outcomes [8–10] and chronic kidney disease [11].

Among the least investigated extrahepatic complications related to MASLD, an ever-increasing number of observational studies have reported an increased prevalence of urolithiasis in adults with MASLD (as extensively discussed below). Urolithiasis has become one of the most common urinary system diseases worldwide, with an estimated prevalence ranging from ~ 1 to 20% in different regions across the globe [12]. Evidence also suggests that the prevalence of urolithiasis is on the rise globally due to changes in socio-economic conditions, climatic factors and dietary habits, as well as increasing rates of metabolic comorbidities (such as overweight/obesity, metabolic syndrome and type 2 diabetes) [12, 13]. Therefore, the increasing global burden of urolithiasis is expected to have substantial health, economic and social implications in the coming years.

To our knowledge, two previous small meta-analyses (published in 2018) have reported that the risk of urolithiasis in individuals with MASLD appeared to be higher than in those without MASLD [14, 15]. These meta-analyses did not address the question of whether the strength of any association between MASLD and urolithiasis was affected by severity of NAFLD. Notably, after the publication of these two small meta-analyses, it is important to note that new large observational studies have been published on this topic.

We have, therefore, carried out an updated systematic review and meta-analysis of observational studies to quantify the magnitude of the association of urolithiasis in adult individuals with MASLD. We also aimed to examine whether the severity of MASLD was associated with an increased risk of urolithiasis. Clarifying the magnitude of the risk of urolithiasis related to MASLD may favorably impact the development of primary prevention strategies for urolithiasis.

Methods

Registration of review protocol

The protocol of the systematic review was registered on the Open Science Framework (OSF) database (registration DOI: 10.17605/OSF.IO/JVGP2).

Data sources and searches

This systematic review has been performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analysis Of Observational Studies in Epidemiology (MOSE) guidelines [16, 17]. We systematically searched three large electronic databases (PubMed, Web of Science and Scopus) from database inception to March 31, 2024, to identify relevant observational studies examining the association between MASLD and the risk of urolithiasis. Search free text terms were "urolithiasis" OR "nephrolithiasis" OR "renal stones" OR “urinary calculi” AND “fatty liver” OR “non-alcoholic fatty liver disease” OR “NAFLD” OR “non-alcoholic steatohepatitis” OR “metabolic dysfunction-associated steatotic liver disease” OR “MASLD” OR “metabolic dysfunction-associated steatohepatitis” OR “metabolic dysfunction-associated fatty liver disease” OR “MAFLD”. Searches were restricted to human studies and English language studies. Subjects included in the meta-analysis were of either sex without age, race, or ethnicity restrictions.

Study selection

Eligible studies were included in the meta-analysis if they met the following inclusion criteria: (1) observational (cross-sectional, case–control, or longitudinal) studies examining the risk of urolithiasis amongst adult (age ≥ 18 years) individuals with and without MASLD (or NAFLD); (2) studies that reported odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (95% CIs) values for the outcome of interest; (3) the diagnosis of MASLD (or NAFLD) was based on liver biopsy, imaging techniques or blood-based biomarkers/scores, in the absence of significant alcohol consumption (usually defined as < 20 g/day for women and < 30 g/day for men) or other competing causes of hepatic steatosis (e.g., viral hepatitis, iron overload and use of potentially hepatotoxic drugs); and (4) the diagnosis of urolithiasis was based on imaging techniques (ultrasonography or computed tomography) or a self-reported history.

The exclusion criteria of the meta-analysis were as follows: (1) congress abstracts, case reports, reviews, practice guidelines, commentaries or editorials; (2) studies in which the diagnosis of MASLD (or NAFLD) was based exclusively on serum liver enzyme concentrations; (3) studies which did not exclude individuals with significant alcohol consumption or other known causes of chronic liver disease; and 4) studies that included exclusively patient populations with MASLD (or NAFLD) or those with known or suspected urolithiasis.

Data extraction and quality assessment

Data from studies eligible for the aggregate data meta-analysis were independently extracted by two investigators (AM and GT). Any disagreements between investigators about including eligible studies were resolved by consensus and a third investigator if needed (RM).

For each eligible study, we extracted data on publication year, study design, sample size, country, population characteristics, methods used for the diagnosis of MASLD and urolithiasis, outcomes of interest, matching and confounding factors included in multivariable regression analyses, and duration of follow-up (only for longitudinal studies). In the case of multiple publications of the same database, we included the most up-to-date or comprehensive information.

The overall quality of the studies included in the aggregate data meta-analysis was assessed using the Newcastle–Ottawa scale (NOS) by two independent authors (AM and GT). Any disparities in scoring were reviewed, and consensus was obtained following discussion. The NOS scale is a validated scale for non-randomized studies in meta-analyses, which uses a star system to assess the quality of a study in three domains: selection, comparability, and outcome/exposure. The NOS assigns a maximum of four stars for selection (or five stars in the case of cross-sectional studies), two for comparability, and three for outcome/exposure. We judged studies that received a score of at least 8 stars to be at low risk of bias, thus reflecting the highest quality.

Data synthesis and analysis

The primary outcome measure of the meta-analysis was the presence of urolithiasis for cross-sectional studies or the risk of developing incident urolithiasis for longitudinal studies. The ORs (for cross-sectional studies) or HRs (for longitudinal studies) and their 95% CIs were considered as the effect size for all the eligible studies. When studies reported ORs/HRs with varying degrees of covariate adjustment, we extracted those that reflected the maximum extent of adjustment for potentially confounding variables. The adjusted ORs/HRs of all eligible studies were pooled, and an overall effect-size estimate was calculated using a random-effects model since high heterogeneity was expected for a meta-analysis of observational studies.

The statistical heterogeneity among studies was evaluated by the chi-square test and the I2-statistic, which estimates the percentage of variability across studies due to heterogeneity rather than chance alone. The proportion of heterogeneity accounted for by between-study variability was assessed using the I2-statistic and adjudicated to be significant if the I2 index was > 50% [18]. The possibility of publication bias was examined using the visual inspection of funnel plots and the Egger’s regression asymmetry test [19].

To explore the possible sources of (expected) high heterogeneity among the studies and to test the robustness of the observed associations, we performed subgroup analyses by study country (Asian vs. non-Asian countries), diagnostic methods used for identifying MASLD and urolithiasis (computed tomography vs. ultrasonography vs. survey questionnaires), and degrees of covariate adjustment (minimally vs. fully adjusted studies). We also tested for possible excessive influence of individual studies using a meta-analysis influence test that eliminated each included study at a time. Finally, we performed univariable meta-regression analyses to test the impact of age and sex on the effect size for the association between MASLD and urolithiasis.

All statistical tests were two-sided and used a significance level of p < 0.05. We used R version 4.3.3 (R Core Team 2023, R Foundation for Statistical Computing, Vienna, Austria. < https://www.R-project.org/ >) for all statistical analyses with the following packages: meta (version 7.0–0) and metafor (version 4.4–0).

Results

Literature search and characteristics of included studies

The PRISMA flow diagram of the meta-analysis is reported in Supplementary Fig. 1. After examining the titles and abstracts of the publications and excluding duplicates, we identified 13 potentially eligible studies from PubMed, Web of Science, and Scopus from the inception to March 31, 2024. We further excluded five studies because of unsatisfactory inclusion criteria (as reported in Supplementary Table 1). Consequently, we identified eight unique observational studies (7 cross-sectional studies and one prospective cohort study) for inclusion in the meta-analysis.

The main characteristics of these eight selected observational studies are reported in Table 1. Regarding the seven cross-sectional studies [20–26], the diagnoses of MASLD and urolithiasis were based on abdominal ultrasonography (n = 3 studies), non-contrast computed tomography (n = 3 studies), or survey questionnaires (n = 1 study). No studies were available on using liver biopsy to diagnose MASLD. Overall, these cross-sectional studies included 40,385 adult individuals (39.5% men; mean age 47.6 years; ~ 15% had a diagnosis of urolithiasis; ~ 22% had a diagnosis of MASLD). Five studies were conducted in Asia (China, South Korea, Iran, and Israel), one in the USA and one in Colombia. Two of these 7 studies obtained at least 8 stars on the NOS scale, thus reflecting a low risk of bias; two studies obtained 7 stars, and the remaining three studies obtained 6 stars. As shown in Table 1, the single published prospective cohort study was carried out in South Korea and included 208,578 adult individuals undergoing a health checkup examination who were followed for a median period of 6.6 years. The diagnosis of MASLD and urolithiasis was based on ultrasonography [27]. Table 1 Eligible cross-sectional (n = 7) and prospective studies (n = 1) examining the association between MASLD and risk of urolithiasis

Authors, Year (Ref.)	Study design	Study participants	MASLD diagnosis, % of casesa	Urolithiasis diagnosis, % of cases	Covariate adjustments	Study results	NOS	
Cross-sectional studies	
 Einollahi et al. (2013) [20]	Cross-sectional (retrospective analysis)	11,245 Iranian adult individuals (M/F: 5698/5547

mean age: NA

mean BMI: NA

% diabetes: NA)

	Ultrasound,30% (n = 3341)	Ultrasound, 11% (n = 1193)	Sex	MASLD was associated with higher odds of urolithiasis (aOR 2.40, 95% CI 2.1–2.7)	7	
 Nam et al. (2016) [21]	Cross-sectional (retrospective analysis)	1381 South Korean adult individuals (M/F: 684/687

mean age: 55.8 years

mean BMI: NA

% diabetes: NA)

	Non-contrast computed tomography, 18.2% (n = 251)	Non-contrast computed tomography, 11.6% (n = 160)	Age and sex	MASLD was associated with higher odds of urolithiasis (aOR 4.99, 95% CI 3.0–8.2)	6	
 Zeina et al. (2017) [22]	Cross-sectional (retrospective analysis)	508 Israeli adult individuals (M/F: 378/130

mean age: 47.5 years

mean BMI: 29.5 kg/m2

% diabetes: 17.6%)

	Non-contrast computed tomography, 15.7% (n = 80)	Non-contrast computed tomography, 83.9% (n = 421)	Age, sex, CT-measured visceral fat thickness and diabetes	MASLD was associated with higher odds of urolithiasis (aOR 2.52, 95% CI 1.02–6.2)	6	
 Wei et al. (2018) [23]	Population-based cross-sectional (retrospective analysis)	3719 Chinese adult male individuals (M/F: 3,719/0

mean age: 38 years

mean BMI: 23.8 kg/m2

% diabetes: NA)

	Ultrasound, 22.7% (n = 843)	Ultrasound, 4.0% (n = 149)	Age, BMI, education level, smoking, alcohol intake and physical activity	MASLD was associated with higher odds of urolithiasis (aOR, 1.35, 95% CI 1.01–1.81). In addition, increasing ultrasonographic severity of MASLD was associated with higher odds of urolithiasis (absent vs. mild vs. moderate vs. severe MASLD: aOR 0.78, 95% CI 0.51–1.21; aOR 1.23, 95% CI 0.75–2.03; aOR 2.11, 95% CI 1.08–4.14)	8	
 Decker et al. (2020) [24]	Population-based cross-sectional (NHANES III 1988–94) (retrospective analysis)	11,859 United States adult individuals (M/F: 5,450/6,409 mean age: 45 years

mean BMI: NA

% obesity: 26%

% diabetes: 6%)

	Ultrasound, 21.1% (n = 2498)	Survey questionnaires; percentage not available	Age, sex, ethnicity, smoking status, elevated serum liver enzymes, obesity, diabetes,

hypertension and gout

	MASLD was associated with higher odds of urolithiasis in women

(aOR 1.65, 95% CI 1.17–2.32), but not

in men (aOR 1.04, 95% CI 0.77–1.40)

	8	
 Lubinus Badillo et al. (2020) [25]	Cross-sectional (retrospective analysis)	1,010 Colombian adult individuals (M/F: 500/510

mean age: NA

mean BMI: NA

% diabetes: NA)

	Non-contrast computed tomography, 45.3% (n = 458)	Non-contrast computed tomography, 66% (n = 676)	Age and sex	MASLD was associated with higher odds of urolithiasis (aOR, 1.29, 95% CI 1.10–1.53). In addition, increasing ultrasonographic severity of MASLD was associated with higher odds of urolithiasis	6	
 Moftakhar et al. (2022) [26]	Population-based cross-sectional (retrospective analysis)	10,663 Iranian adult individuals (M/F: 4724/5939

mean age: 52 years

mean BMI: NA

% obesity: 18%

% diabetes: 15%)

	Survey questionnaires, 12.1% (n = 1285)	Survey questionnaires, 21.1% (n = 2251)	Age, sex, socioeconomic status, obesity, hypertension and diabetes	MASLD was associated with higher odds of urolithiasis (aOR, 2.21, 95% CI 1.93–2.52)	7	
Prospective cohort studies	
 Kim S et al. (2017) [27]	Prospective (retrospective analysis)	208,578 South Korean adult individuals who underwent a health check-up examination (M/F: 112,324/96,254

mean age: 38 years

mean BMI: 24 kg/m2

% diabetes: 3% (n = 1593)). Median follow-up: 6.6 years (IQR 3.0–9.4 years)

	Ultrasound, 24.4% (n = 50,964)	Ultrasound, n = 16,442 cases of incident urolithiasis over the follow-up (overall incidence rate, 1.6 per 100 person-years)	Age, center, year of screening exam, smoking, alcohol intake, physical activity, education level, BMI, hypertension, diabetes, HOMA-IR, C-reactive protein and uric acid	MASLD was associated with a higher risk of developing incident urolithiasis in men (aHR 1.17, 95% CI 1.06–1.30), but not in women (aHR 0.97, 95% CI 0.81–1.16)	8	
NA not available, aOR adjusted odds ratio, aHR adjusted hazard ratio, BMI body mass index, HOMA-IR homeostasis model assessment-insulin resistance, NOS Newcastle–Ottawa Scale

aOriginally labelled as NAFLD

Cross-sectional studies on the association between MASLD and urolithiasis

The distribution of cross-sectional studies (n = 7 studies involving 40,385 adult individuals from different countries) by estimate of the association between MASLD and the risk of prevalent urolithiasis is plotted in Fig. 1. We found that MASLD was significantly associated with a higher risk of prevalent urolithiasis (pooled random-effects OR 1.87, 95% CI 1.34–2.60; I2 = 91%). In most eligible studies, these results persisted when adjusted for age, sex, obesity, hypertension, type 2 diabetes, and other potential confounding factors (as specified in Table 1).Fig. 1 Forest plot and pooled estimates of the effect of MASLD on the risk of prevalent urolithiasis in the eligible cross-sectional studies

Subgroup analyses

We undertook subgroup analyses to explore the possible sources of high heterogeneity across the cross-sectional studies. As shown in Supplementary Fig. 2, the association between MASLD and urolithiasis was stronger in Asian studies (n = 5 studies; pooled random-effects OR 2.38, 95% CI 1.58–3.57; I2 = 83%) than in non-Asian studies (n = 2 studies; random-effects OR 1.29, 95% CI 1.04–1.59; I2 = 51%). Conversely, the association between MASLD and urolithiasis was consistent when the comparison was stratified by different methods used for diagnosing MASLD (or urolithiasis) (Supplementary Fig. 3) or by the degree of covariate adjustment [pooled random-effects OR 2.42, 95% CI 1.15–5.09 for minimally adjusted studies (i.e., adjusted for age and sex), and pooled random-effects OR 1.59, 95% CI 1.12–2.17 for fully adjusted studies (i.e., adjusted for age, sex, obesity and other common metabolic risk factors)] (Supplementary Fig. 4).

Sensitivity analyses and meta-regressions

A sensitivity analysis using the one-study remove (leave-one-out) approach to test the influence of each study on the overall effect size showed that eliminating each of the cross-sectional studies from the pooled primary analysis did not have any significant effect on the association between MASLD and urolithiasis (Supplementary Fig. 5). The results of univariable meta-regression analyses to examine the effect of potential moderator variables showed a significant positive association between age and urolithiasis (p = 0.011) (Supplementary Fig. 6). Conversely, meta-regression analysis did not show any significant effect of sex on the association between MASLD and urolithiasis (in cross-sectional studies) (p = 0.361) (Supplementary Fig. 7). As reported in Table 1, there were insufficient data to perform univariable meta-regression analyses for testing the effects of obesity and diabetes on the presence of urolithiasis.

Cross-sectional studies on the association between more severe MASLD and urolithiasis

The distribution of cross-sectional studies by estimate of the association between the ultrasonographic severity of MASLD and the risk of prevalent urolithiasis is plotted in Fig. 2 [23, 25]. We found that more severe MASLD on ultrasonography was significantly associated with higher odds of urolithiasis (pooled random-effects OR 2.0, 95% CI 1.46–2.74; I2 = 0%). None of the eligible studies examined the association between blood-based biomarkers of liver fibrosis and the likelihood of urolithiasis.Fig. 2 Forest plot and pooled estimates of the effect of ultrasonographic severity of MASLD on the risk of prevalent urolithiasis in the eligible cross-sectional studies

Longitudinal studies on the association between MALD and risk of developing urolithiasis

The distribution of cohort studies by estimate of the association between MASLD and the risk of developing incident urolithiasis is plotted in Fig. 3. Only one cohort study from South Korea examined the association between MASLD and the risk of developing urolithiasis amongst 208,578 adult individuals undergoing health checkup examinations [27]. During a median follow-up of 6.6 years, there were 16,442 cases of incident urolithiasis. MASLD assessed by ultrasonography was significantly associated with a higher risk of incident urolithiasis in men (adjusted HR 1.17, 95% CI 1.06–1.30) but not in women (adjusted HR 0.97, 95% CI 0.81–1.16) after adjusting for common metabolic risk factors and other potential confounders. As shown in Fig. 2, when we plotted these two adjusted HRs in a forest plot analysis, MAFLD was not significantly associated with the risk of developing urolithiasis (pooled random-effects HR 1.08, 95% CI 0.90–1.30; I2 = 69%).Fig. 3 Forest plot and pooled estimates of the effect of MASLD on the risk of developing incident urolithiasis in the eligible cohort studies

Publication bias

As shown in Fig. 4, the visual inspection and the Egger’s regression test (although less than ten studies were included) did not show any statistically significant asymmetry of the funnel plot for the included studies (p = 0.769), thus suggesting that the publication bias was low.Fig. 4 Funnel plot assessing the possibility of publication bias across the eligible studies (n = 8)

Discussion

In this comprehensive and updated meta-analysis that included 8 observational studies (seven cross-sectional studies and one longitudinal cohort study) with aggregate data on ~ 250,000 adult individuals from different countries, we found that MASLD was significantly associated with an approximately two-fold higher prevalence of urolithiasis (n = 7 studies; pooled random-effects OR 1.87, 95% CI 1.34–2.60). This association was more robust in studies conducted in Asia than in non-Asian countries but remained unchanged when the comparison was stratified by different modalities for diagnosing MASLD or urolithiasis. Notably, this association remained significant in those studies where statistical analysis was adjusted for age, sex, ethnicity, obesity, type 2 diabetes, and other common metabolic risk factors. Moreover, the ultrasonographic severity of MASLD was significantly associated with higher odds of urolithiasis. Meta-regression analyses also showed a significant positive association between age and MASLD-related urolithiasis, suggesting that this association may be partly mediated by age population in different studies (thus explaining a part of the observed high heterogeneity among studies). Finally, the meta-analysis of data from the single Asian cohort study suggested that MAFLD was not associated with the risk of developing incident urolithiasis (pooled random-effects HR 1.08, 95% CI 0.90–1.30), although there was a significant interaction between sex and MASLD for the development of nephrolithiasis (MASLD being significantly associated with a higher risk of developing urolithiasis in men but not in women). Further well-designed prospective studies in Asian and non-Asian populations are needed to better understand whether MASLD may be a risk factor for incident urolithiasis Adequate consideration of sex differences and sex hormones/menopausal status in future clinical investigations will be also needed to fill current gaps and implement precision medicine. Further research is also required to elucidate whether the severity of MASLD (especially higher fibrosis stage, which is the strongest histologic predictor of hepatic and extrahepatic morbidity and mortality in MASLD [4, 28]) may adversely affect the risk of urolithiasis.

To our knowledge, this is the most updated and comprehensive meta-analysis assessing the association between MASLD and the risk of having or developing urolithiasis. Our findings corroborate and further expand the results of two previous meta-analyses published in 2018 [14, 15]. Unlike these two smaller meta-analyses, we included three large observational studies (published in 2020 and 2022) and performed separate analyses for cross-sectional and longitudinal studies (although only one Asian prospective cohort study was available so far), thus examining the possible distinct effects of MASLD on the prevalence and incidence of urolithiasis. Furthermore, our subgroup analyses and meta-regressions confirmed the robustness of the observed associations. Contrary to these previous meta-analyses [14, 15], we did not include “grey” literature, as we excluded unpublished studies and studies published outside widely available journals. Therefore, we did not include two cross-sectional studies from Colombia and Israel of very low quality that were published only as poster communications (as specified in our Supplementary material).

The findings of our meta-analysis may have some important clinical implications; more specifically, adult patients with MASLD may be screened for urolithiasis (especially in Asian people with MASLD) as these patients are at higher risk of urolithiasis. A recent Mendelian randomization study revealed no genetic evidence for a causal relationship between genetically predicted MASLD and the risk of urolithiasis [29]. Hence, routine screening for urolithiasis in patients with MASLD might seem poorly supported by current evidence. However, it should be noted that this Mendelian randomization study had some important limitations. First, the diagnosis of urolithiasis was based exclusively on International Classification of Disease (ICD) codes in the genome-wide association studies (GWAS) data (thus reducing the diagnostic accuracy in identifying MASLD). Second, the dataset included only individuals of European ancestry, so these results may not be generalizable to other ethnic populations [29].

There is intense debate about the independent contribution of steatotic/inflamed or fibrosing liver to the pathophysiology of urolithiasis in patients with MASLD. It is beyond the scope of this meta-analysis to discuss in detail the precise mechanisms whereby MASLD may contribute to the development of urolithiasis. Although further mechanistic studies are needed for establishing a cause-effect relationship between MASLD and the risk of urolithiasis, there is accumulating evidence of biological plausibility that MASLD may increase the risk of urolithiasis. MASLD and urolithiasis share multiple metabolic risk factors, such as obesity, dyslipidemia, type 2 diabetes and hyperuricemia/gout [30–32]. However, accumulating evidence indicates that MASLD may release multiple proinflammatory, lipotoxic and prooxidant mediators and exacerbate hepatic and systemic insulin resistance, i.e., a pathogenic factor in MASLD development, thus further contributing to the formation of renal stones. Insulin resistance may interfere with renal acid excretion and purine metabolism, causing unduly acidic urine pH and reduced urinary ammonium excretion [33, 34]. Insulin resistance may also act at the renal level by specific defects of basolateral transporters on the membrane and possibly by affecting the gatekeepers of the glomerular filtration barrier [34]. Preliminary evidence suggests that patients with MASLD also have a distinct urinary lithogenic risk profile characterized by reduced urinary magnesium and altered urinary ammonium excretion [35]. That said, it should be noted that none of the eligible studies had data on the chemical composition of renal stones, precluding any inference about the pathophysiological mechanisms potentially involved in the development of urolithiasis.

Our meta-analysis has some important limitations inherent to the design of the eligible studies. First, since the included studies had a retrospective cross-sectional (n = 7 studies) or prospective (only one study) design, it does not allow for the establishment of a cause-effect relationship between MASLD and urolithiasis. Second, although most studies adjusted the results for age, sex, smoking history and common shared metabolic comorbidities (such as obesity, type 2 diabetes and, in some cases, hyperuricemia/gout), the possibility of residual confounding by unmeasured factors (e.g., dietary habits) cannot be entirely excluded. Third, although we used a random-effects model, the interpretation of some meta-analysis results requires some caution because of the observed medium–high heterogeneity for the pooled primary analysis of studies and the relatively low quality of the studies, suggesting a medium–high risk of bias according to the NOS. Fourth, some studies diagnosed urolithiasis using survey questionnaires or ultrasonography, and only three studies used non-contrast computed tomography, which is the most accurate imaging method for detecting renal stones [36]; similarly, MASLD was diagnosed using imaging methods but not liver biopsy (i.e., the ‘gold standard’ for diagnosing and staging MASLD) [37, 38]. Therefore, it is hoped that more studies will use non-contrast computed tomography to diagnose urolithiasis in the future. Fifth, although all eligible studies have used the NAFLD nomenclature, for this meta-analysis, we have assumed that NAFLD and MASLD are synonymous, as the two fatty liver disease definitions share a very high level of overlap (> 95% of individuals with NAFLD meet the criteria for MASLD) [39, 40]. Finally, although a selective reporting bias of eligible studies could not be excluded, our comprehensive search has made it unlikely that any published studies were missed.

Notwithstanding these limitations, this meta-analysis also has important strengths. Our meta-analysis is the most comprehensive assessment of the association between MASLD and the risk of urolithiasis. The large number of individuals included (although the limited number of studies available so far) provided sufficient statistical power to quantify the magnitude of the association between MASLD and urolithiasis. Moreover, we used standardized risk estimates from all included studies to allow a consistent combination of estimates across eligible studies. Finally, the visual inspection of funnel plot did not reveal any significant asymmetry, thus suggesting that the risk of publication bias was low.

In conclusion, this updated meta-analysis of observational studies provides evidence for a significant association between MASLD and urolithiasis. This association was stronger in studies carried out in Asia than in non-Asian countries and remained statistically significant in those studies whose results were adjusted for age, sex, ethnicity, obesity, diabetes, and other potential confounders. There was a positive graded association between the ultrasonographic severity of MASLD and the presence of urolithiasis. It remains to be established whether individuals with MASLD also have a higher risk of developing incident urolithiasis. Future well-designed prospective studies in both Asian and non-Asian populations (possibly using vibration-controlled transient elastography or magnetic resonance-based techniques for diagnosing MASLD and using non-contrast computed tomography for detecting urolithiasis) are needed to further corroborate these findings and mechanistic studies to better decipher the complex mechanisms underpinning the association between MASLD and urolithiasis.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (PDF 504 KB)

Abbreviations

NAFLD Non-alcoholic fatty liver disease

MASLD Metabolic dysfunction-associated steatotic liver disease

PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses

NOS Newcastle–Ottawa Quality Assessment Scale

OR Odds ratio

HR Hazard ratio

Author contributions

AM and GT were involved in the conception of the study and the analysis and interpretation of the results. GT wrote the first draft of the manuscript. RM, VF, and MGL were involved in the conduct of the study and searched the published articles. SP and PMF was involved in the interpretation of the results and contributed to the discussion. All authors edited, reviewed, and approved the final version of the manuscript.

Funding

Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement. There was no funding source for this study.

Data availability

All supporting data of the meta-analysis are available within the article and in the online-only Supplementary Material.

Declarations

Conflict of interest

The authors have no potential conflicts of interest to disclose.

Human and animal rights statement and Informed consent

This study involves human participants but was not approved by an Ethics Committee. Approval from an Ethics Committee is not necessary as this is a meta-analysis of published observational studies that had already obtained both informed consent from participants and ethical approval by their local Ethics committees.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Rinella ME Lazarus JV Ratziu V Francque SM Sanyal AJ Kanwal F A multisociety Delphi consensus statement on new fatty liver disease nomenclature J Hepatol 2023 79 6 1542 1556 10.1016/j.jhep.2023.06.003 37364790
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79(6):1542–1556. 10.1016/j.jhep.2023.06.003. (PubMed PMID: 37364790)37364790 10.1016/j.jhep.2023.06.003
2. Miao L Targher G Byrne CD Cao YY Zheng MH Current status and future trends of the global burden of MASLD Trends Endocrinol Metab 2024 10.1016/j.tem.2024.02.007 38429161
Miao L, Targher G, Byrne CD, Cao YY, Zheng MH (2024) Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 10.1016/j.tem.2024.02.007. (PubMed PMID: 38429161)38429161 10.1016/j.tem.2024.02.007
3. Wong VW Ekstedt M Wong GL Hagstrom H Changing epidemiology, global trends and implications for outcomes of NAFLD J Hepatol 2023 79 3 842 852 10.1016/j.jhep.2023.04.036 37169151
Wong VW, Ekstedt M, Wong GL, Hagstrom H (2023) Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 79(3):842–852. 10.1016/j.jhep.2023.04.036. (PubMed PMID: 37169151)37169151 10.1016/j.jhep.2023.04.036
4. Targher G Tilg H Byrne CD Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach Lancet Gastroenterol Hepatol. 2021 6 7 578 588 10.1016/S2468-1253(21)00020-0 33961787
Targher G, Tilg H, Byrne CD (2021) Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 6(7):578–588. 10.1016/S2468-1253(21)00020-0. (PubMed PMID: 33961787)33961787 10.1016/S2468-1253(21)00020-0
5. Zhao J Liu L Cao YY Gao X Targher G Byrne CD MAFLD as part of systemic metabolic dysregulation Hepatol Int 2024 10.1007/s12072-024-10660-y 39249647
Zhao J, Liu L, Cao YY, Gao X, Targher G, Byrne CD et al (2024) MAFLD as part of systemic metabolic dysregulation. Hepatol Int. 10.1007/s12072-024-10660-y. (PubMed PMID: 38594474)39249647 10.1007/s12072-024-10660-y
6. Mantovani A Petracca G Beatrice G Csermely A Tilg H Byrne CD Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies Gut 2022 71 4 778 788 10.1136/gutjnl-2021-324191 33685968
Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD et al (2022) Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 71(4):778–788. 10.1136/gutjnl-2021-324191. (PubMed PMID: 33685968)33685968 10.1136/gutjnl-2021-324191
7. Mantovani A Petracca G Beatrice G Tilg H Byrne CD Targher G Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals Gut 2021 70 5 962 969 10.1136/gutjnl-2020-322572 32938692
Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G (2021) Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70(5):962–969. 10.1136/gutjnl-2020-322572. (PubMed PMID: 32938692)32938692 10.1136/gutjnl-2020-322572
8. Mantovani A Csermely A Petracca G Beatrice G Corey KE Simon TG Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis Lancet Gastroenterol Hepatol. 2021 6 11 903 913 10.1016/S2468-1253(21)00308-3 34555346
Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG et al (2021) Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 6(11):903–913. 10.1016/S2468-1253(21)00308-3. (PubMed PMID: 34555346)34555346 10.1016/S2468-1253(21)00308-3
9. Targher G Byrne CD Tilg H MASLD: a systemic metabolic disorder with cardiovascular and malignant complications Gut 2024 73 4 691 702 10.1136/gutjnl-2023-330595 38228377
Targher G, Byrne CD, Tilg H (2024) MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73(4):691–702. 10.1136/gutjnl-2023-330595. (PubMed PMID: 38228377)38228377 10.1136/gutjnl-2023-330595
10. Galiero R Caturano A Vetrano E Cesaro A Rinaldi L Salvatore T Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease Rev Cardiovasc Med 2021 22 3 755 768 10.31083/j.rcm2203082 34565074
Galiero R, Caturano A, Vetrano E, Cesaro A, Rinaldi L, Salvatore T et al (2021) Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Rev Cardiovasc Med 22(3):755–768. 10.31083/j.rcm2203082. (PubMed PMID: 34565074)34565074 10.31083/j.rcm2203082
11. Mantovani A Petracca G Beatrice G Csermely A Lonardo A Schattenberg JM Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis Gut 2022 71 1 156 162 10.1136/gutjnl-2020-323082 33303564
Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM et al (2022) Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut 71(1):156–162. 10.1136/gutjnl-2020-323082. (PubMed PMID: 33303564)33303564 10.1136/gutjnl-2020-323082
12. Lang J Narendrula A El-Zawahry A Sindhwani P Ekwenna O Global trends in incidence and burden of urolithiasis from 1990 to 2019: an analysis of Global Burden of Disease Study Data Eur Urol Open Sci. 2022 35 37 46 10.1016/j.euros.2021.10.008 35024630
Lang J, Narendrula A, El-Zawahry A, Sindhwani P, Ekwenna O (2022) Global trends in incidence and burden of urolithiasis from 1990 to 2019: an analysis of Global Burden of Disease Study Data. Eur Urol Open Sci. 35:37–46. 10.1016/j.euros.2021.10.008. (PubMed PMID: 35024630; PubMed Central PMCID: PMCPMC8738898)35024630 10.1016/j.euros.2021.10.008
13. Qian X Wan J Xu J Liu C Zhong M Zhang J Epidemiological trends of urolithiasis at the global, regional, and national levels: a population-based study Int J Clin Pract 2022 10.1155/2022/6807203 36628152
Qian X, Wan J, Xu J, Liu C, Zhong M, Zhang J et al (2022) Epidemiological trends of urolithiasis at the global, regional, and national levels: a population-based study. Int J Clin Pract. 10.1155/2022/6807203. (PubMed PMID: 35685546; PubMed Central PMCID: PMCPMC9159214)36628152 10.1155/2022/6807203
14. Qin S Wang S Wang X Wang J Non-alcoholic fatty liver disease and the risk of urolithiasis: a systematic review and meta-analysis Medicine (Baltimore) 2018 97 35 e12092 10.1097/MD.0000000000012092 30170429
Qin S, Wang S, Wang X, Wang J (2018) Non-alcoholic fatty liver disease and the risk of urolithiasis: a systematic review and meta-analysis. Medicine (Baltimore) 97(35):e12092. 10.1097/MD.0000000000012092. (PubMed PMID: 30170429; PubMed Central PMCID: PMCPMC6392955)30170429 10.1097/MD.0000000000012092
15. Wijarnpreecha K Lou S Panjawatanan P Sanguankeo A Pungpapong S Lukens FJ Nonalcoholic fatty liver disease and urolithiasis. A systematic review and meta-analysis J Gastrointestin Liver Dis 2018 27 4 427 432 10.15403/jgld.2014.1121.274.nac 30574625
Wijarnpreecha K, Lou S, Panjawatanan P, Sanguankeo A, Pungpapong S, Lukens FJ et al (2018) Nonalcoholic fatty liver disease and urolithiasis. A systematic review and meta-analysis. J Gastrointestin Liver Dis 27(4):427–432. 10.15403/jgld.2014.1121.274.nac. (PubMed PMID: 30574625)30574625 10.15403/jgld.2014.1121.274.nac
16. Page MJ McKenzie JE Bossuyt PM Boutron I Hoffmann TC Mulrow CD The PRISMA 2020 statement: an updated guideline for reporting systematic reviews Syst Rev 2021 10 1 89 10.1186/s13643-021-01626-4 33781348
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1):89. 10.1186/s13643-021-01626-4. (PubMed PMID: 33781348; PubMed Central PMCID: PMCPMC8008539)33781348 10.1186/s13643-021-01626-4
17. Stroup DF Berlin JA Morton SC Olkin I Williamson GD Rennie D Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 2000 283 15 2008 2012 10.1001/jama.283.15.2008 10789670
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012. 10.1001/jama.283.15.2008. (PubMed PMID: 10789670)10789670 10.1001/jama.283.15.2008
18. Higgins JP Thompson SG Quantifying heterogeneity in a meta-analysis Stat Med 2002 21 11 1539 1558 10.1002/sim.1186 12111919
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. 10.1002/sim.1186. (PubMed PMID: 12111919)12111919 10.1002/sim.1186
19. Egger M Davey Smith G Schneider M Minder C Bias in meta-analysis detected by a simple, graphical test BMJ 1997 315 7109 629 634 10.1136/bmj.315.7109.629 9310563
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634. 10.1136/bmj.315.7109.629. (PubMed PMID: 9310563; PubMed Central PMCID: PMCPMC2127453)9310563 10.1136/bmj.315.7109.629
20. Einollahi B Naghii MR Sepandi M Association of nonalcoholic fatty liver disease (NAFLD) with urolithiasis Endocr Regul 2013 47 1 27 32 10.4149/endo_2013_01_27 23363254
Einollahi B, Naghii MR, Sepandi M (2013) Association of nonalcoholic fatty liver disease (NAFLD) with urolithiasis. Endocr Regul 47(1):27–32. 10.4149/endo_2013_01_27. (PubMed PMID: 23363254)23363254 10.4149/endo_2013_01_27
21. Nam IC Association of non-alcoholic fatty liver disease with renal stone disease detected on computed tomography Eur J Radiol Open. 2016 3 195 199 10.1016/j.ejro.2016.07.004 27536709
Nam IC (2016) Association of non-alcoholic fatty liver disease with renal stone disease detected on computed tomography. Eur J Radiol Open. 3:195–199. 10.1016/j.ejro.2016.07.004. (PubMed PMID: 27536709; PubMed Central PMCID: PMCPMC4976131)27536709 10.1016/j.ejro.2016.07.004
22. Zeina AR Goldenberg L Nachtigal A Hasadia R Saliba W Association between nephrolithiasis and fatty liver detected on non-enhanced CT for clinically suspected renal colic Clin Imaging 2017 43 148 152 10.1016/j.clinimag.2017.03.011 28324714
Zeina AR, Goldenberg L, Nachtigal A, Hasadia R, Saliba W (2017) Association between nephrolithiasis and fatty liver detected on non-enhanced CT for clinically suspected renal colic. Clin Imaging 43:148–152. 10.1016/j.clinimag.2017.03.011. (PubMed PMID: 28324714)28324714 10.1016/j.clinimag.2017.03.011
23. Wei YP Lin XG He RQ Shen J Sun SL Chen G Epidemiologic association of nonalcoholic fatty liver disease and urinary calculi: a population-based cross-sectional study in Southern China Iran J Kidney Dis 2018 12 2 112 119 29507274
Wei YP, Lin XG, He RQ, Shen J, Sun SL, Chen G et al (2018) Epidemiologic association of nonalcoholic fatty liver disease and urinary calculi: a population-based cross-sectional study in Southern China. Iran J Kidney Dis 12(2):112–119 (Epub 2018/03/07 PubMed PMID: 29507274)29507274
24. Decker RD Ghiraldi EM Weiss AH Gaughan JP Friedlander JI Nonalcoholic fatty liver disease is an independent risk factor for nephrolithiasis in women: findings from NHANES III J Endourol 2020 34 12 1258 1262 10.1089/end.2020.0486 32571100
Decker RD, Ghiraldi EM, Weiss AH, Gaughan JP, Friedlander JI (2020) Nonalcoholic fatty liver disease is an independent risk factor for nephrolithiasis in women: findings from NHANES III. J Endourol 34(12):1258–1262. 10.1089/end.2020.0486. (PubMed PMID: 32571100)32571100 10.1089/end.2020.0486
25. Lubinus Badillo G Cal OLO Vera Campos N Villarreal Ibanez D Relationship between urolithiasis and fatty liver disease: findings in computed tomography Tomography 2020 6 1 1 4 10.18383/j.tom.2020.00020 32280744
Lubinus Badillo G, Cal OLO, Vera Campos N, Villarreal Ibanez D (2020) Relationship between urolithiasis and fatty liver disease: findings in computed tomography. Tomography 6(1):1–4. 10.18383/j.tom.2020.00020. (PubMed PMID: 32280744; PubMed Central PMCID: PMCPMC7138524)32280744 10.18383/j.tom.2020.00020
26. Moftakhar L Jafari F Ghoddusi Johari M Rezaeianzadeh R Hosseini SV Rezaianzadeh A Prevalence and risk factors of kidney stone disease in population aged 40–70 years old in Kharameh cohort study: a cross-sectional population-based study in southern Iran BMC Urol 2022 22 1 205 10.1186/s12894-022-01161-x 36536352
Moftakhar L, Jafari F, Ghoddusi Johari M, Rezaeianzadeh R, Hosseini SV, Rezaianzadeh A (2022) Prevalence and risk factors of kidney stone disease in population aged 40–70 years old in Kharameh cohort study: a cross-sectional population-based study in southern Iran. BMC Urol 22(1):205. 10.1186/s12894-022-01161-x. (PubMed PMID: 36536352; PubMed Central PMCID: PMCPMC9764470)36536352 10.1186/s12894-022-01161-x
27. Kim S Chang Y Sung E Kim CH Yun KE Jung HS Non-alcoholic fatty liver disease and the development of nephrolithiasis: a cohort study PLoS ONE 2017 12 10 e0184506 10.1371/journal.pone.0184506 29073130
Kim S, Chang Y, Sung E, Kim CH, Yun KE, Jung HS et al (2017) Non-alcoholic fatty liver disease and the development of nephrolithiasis: a cohort study. PLoS ONE 12(10):e0184506. 10.1371/journal.pone.0184506. (PubMed PMID: 29073130; PubMed Central PMCID: PMCPMC5657618)29073130 10.1371/journal.pone.0184506
28. Mantovani A Scorletti E Mosca A Alisi A Byrne CD Targher G Complications, morbidity and mortality of nonalcoholic fatty liver disease Metabolism 2020 111S 154170 10.1016/j.metabol.2020.154170 32006558
Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G (2020) Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 111S:154170. 10.1016/j.metabol.2020.154170. (PubMed PMID: 32006558)32006558 10.1016/j.metabol.2020.154170
29. Li X Xie Y Tang L Li D Wang J Sheng H A two-sample mendelian randomization analysis excludes causal relationships between non-alcoholic fatty liver disease and kidney stones Front Endocrinol (Lausanne). 2023 14 1343367 10.3389/fendo.2023.1343367 38269249
Li X, Xie Y, Tang L, Li D, Wang J, Sheng H et al (2023) A two-sample mendelian randomization analysis excludes causal relationships between non-alcoholic fatty liver disease and kidney stones. Front Endocrinol (Lausanne). 14:1343367. 10.3389/fendo.2023.1343367. (PubMed PMID: 38269249; PubMed Central PMCID: PMCPMC10807291)38269249 10.3389/fendo.2023.1343367
30. Daudon M Haymann JP Estrade V Meria P Almeras C Lithiasis Committee of the French Association of U 2022 Recommendations of the AFU Lithiasis Committee: epidemiology, stone analysis and composition Prog Urol 2023 33 14 737 765 10.1016/j.purol.2023.08.013 37918977
Daudon M, Haymann JP, Estrade V, Meria P, Almeras C, Lithiasis Committee of the French Association of U (2023) 2022 Recommendations of the AFU Lithiasis Committee: epidemiology, stone analysis and composition. Prog Urol 33(14):737–765. 10.1016/j.purol.2023.08.013. (PubMed PMID: 37918977)37918977 10.1016/j.purol.2023.08.013
31. Stamatelou K Goldfarb DS Epidemiology of kidney stones Healthcare (Basel). 2023 10.3390/healthcare11030424 36766999
Stamatelou K, Goldfarb DS (2023) Epidemiology of kidney stones. Healthcare (Basel). 10.3390/healthcare11030424. (PubMed PMID: 36766999; PubMed Central PMCID: PMCPMC9914194)36766999 10.3390/healthcare11030424
32. Wollin DA Skolarikos A Preminger GM Obesity and metabolic stone disease Curr Opin Urol 2017 27 5 422 427 10.1097/MOU.0000000000000427 28650866
Wollin DA, Skolarikos A, Preminger GM (2017) Obesity and metabolic stone disease. Curr Opin Urol 27(5):422–427. 10.1097/MOU.0000000000000427. (PubMed PMID: 28650866)28650866 10.1097/MOU.0000000000000427
33. Moe OW Kidney stones: pathophysiology and medical management Lancet 2006 367 9507 333 344 10.1016/S0140-6736(06)68071-9 16443041
Moe OW (2006) Kidney stones: pathophysiology and medical management. Lancet 367(9507):333–344. 10.1016/S0140-6736(06)68071-9. (PubMed PMID: 16443041)16443041 10.1016/S0140-6736(06)68071-9
34. Spatola L Ferraro PM Gambaro G Badalamenti S Dauriz M Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus Metabolism 2018 83 225 233 10.1016/j.metabol.2018.02.008 29510180
Spatola L, Ferraro PM, Gambaro G, Badalamenti S, Dauriz M (2018) Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus. Metabolism 83:225–233. 10.1016/j.metabol.2018.02.008. (PubMed PMID: 29510180)29510180 10.1016/j.metabol.2018.02.008
35. Bargagli M Liguori A Napodano C Baroni S Tomasello L Pizzolante F Urinary lithogenic profile of patients with non-alcoholic fatty liver disease Nephrol Dial Transplant 2023 38 11 2652 2654 10.1093/ndt/gfad106 37253621
Bargagli M, Liguori A, Napodano C, Baroni S, Tomasello L, Pizzolante F et al (2023) Urinary lithogenic profile of patients with non-alcoholic fatty liver disease. Nephrol Dial Transplant 38(11):2652–2654. 10.1093/ndt/gfad106. (PubMed PMID: 37253621)37253621 10.1093/ndt/gfad106
36. Vijayakumar M Ganpule A Singh A Sabnis R Desai M Review of techniques for ultrasonic determination of kidney stone size Res Rep Urol. 2018 10 57 61 10.2147/RRU.S128039 30128307
Vijayakumar M, Ganpule A, Singh A, Sabnis R, Desai M (2018) Review of techniques for ultrasonic determination of kidney stone size. Res Rep Urol. 10:57–61. 10.2147/RRU.S128039. (PubMed PMID: 30128307; PubMed Central PMCID: PMCPMC6089602)30128307 10.2147/RRU.S128039
37. Byrne CD Patel J Scorletti E Targher G Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults BMJ 2018 362 k2734 10.1136/bmj.k2734 30002017
Byrne CD, Patel J, Scorletti E, Targher G (2018) Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ 362:k2734. 10.1136/bmj.k2734. (PubMed PMID: 30002017)30002017 10.1136/bmj.k2734
38. Tilg H Byrne CD Targher G NASH drug treatment development: challenges and lessons Lancet Gastroenterol Hepatol. 2023 8 10 943 954 10.1016/S2468-1253(23)00159-0 37597527
Tilg H, Byrne CD, Targher G (2023) NASH drug treatment development: challenges and lessons. Lancet Gastroenterol Hepatol. 8(10):943–954. 10.1016/S2468-1253(23)00159-0. (PubMed PMID: 37597527)37597527 10.1016/S2468-1253(23)00159-0
39. Hagstrom H Vessby J Ekstedt M Shang Y 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical J Hepatol 2024 80 2 e76 e77 10.1016/j.jhep.2023.08.026 37678723
Hagstrom H, Vessby J, Ekstedt M, Shang Y (2024) 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol 80(2):e76–e77. 10.1016/j.jhep.2023.08.026. (PubMed PMID: 37678723)37678723 10.1016/j.jhep.2023.08.026
40. Younossi ZM Paik JM Stepanova M Ong J Alqahtani S Henry L Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease J Hepatol 2024 10.1016/j.jhep.2024.01.014 39208992
Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L (2024) Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 10.1016/j.jhep.2024.01.014. (PubMed PMID: 38286339)39208992 10.1016/j.jhep.2024.01.014
